“…In recent years, groups, such as Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) have explored both MCID and defining LDAS [17,56]. Recently, this has evolved into the minimal clinically important improvement (MCII) and the PASS in the work of Tubach et al, , 2006Tubach et al, , 2009. These were not included in the current evaluation as our data collection overlapped with the publication, and we did not field the indicators needed for MCII and PASS.…”